(AIM: SAR)

7 February 2013

SAREUM HOLDINGS PLC

(“Sareum” or the “Company”)

US Patent Grant for Sareum’s Kinase Inhibitors

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that the U.S. Patent and Trademark Office has issued notification that a patent will be granted for one of Sareum’s key drug discovery inventions on 19 February 2013.

This patent*, which relates to compounds that inhibit or modulate the activity of kinase enzymes, forms the basis of Sareum’s SKIL® drug discovery platform. The granting of this patent means that Sareum has approved patent protection in the US for key elements of its SKIL platform and many of its drug discovery programmes. The Company expects to receive similar protection in Europe and other major markets in due course.

SKIL (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

* Patent No. US 8,378,095,

Sareum’s CSO, Dr John Reader, commented: “This first grant of a patent for Sareum significantly strengthens our patent portfolio, and enhances our negotiating position with potential licensing and collaboration partners”.

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / Deepak Reddy

020 7947 4350

The Communications Portfolio (Media enquiries)

 

Philip Ranger / Caolan Mahon
philip.ranger@communications-portfolio.co.uk

020 7536 2028 / 2029

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk